相关实验视频
Updated: May 5, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
12.5K
在实验性心肌梗塞后,通过内皮氧化合成酶增强剂AVE9488改善左心室重塑
Daniela Fraccarollo1, Julian D Widder, Paolo Galuppo
1Medizinische Klinik und Poliklinik I, Universitätsklinikum, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.
Circulation
|August 6, 2008
概括
eNOS增强剂AVE9488改善了心脏功能,并减少了小鼠在心肌梗塞后的心脏重塑. 这表明增加内皮氧化 (NO) 是对心力衰竭的有希望的治疗方法.
科学领域:
- 心血管研究研究心血管研究
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 降低内皮氧化 (NO) 生物可用性是心力衰竭进展的关键因素.
- 心肌梗塞 (MI) 导致有害的心脏重塑和功能障碍.
研究的目的:
- 为了研究AVE9488的治疗潜力,一个内皮NO合成酶 (eNOS) 增强剂,改善心脏重塑和心脏衰竭后的MI.
- 为了确定AVE9488是否可以恢复内皮功能并减少实验性MI后的不良分子变化.
主要方法:
- 患有心脏病的老鼠被用AVE9488或安慰剂治疗了9周.
- 评估了左心室 (LV) 功能,压力和重塑标记.
- 评估了eNOS水平,NOS活动和血管功能.
- 在eNOS缺乏的小鼠身上进行了研究,以确认它的作用机制.
主要成果:
- AVE9488显著改善了LV功能,降低了填充压力,并防止了不利的压力-体积曲线变化.
- 治疗减弱的肺,肺纤维化,肌细胞缩和亲缩的基因表达.
- 在心肌梗塞中,AVE9488使降低的eNOS水平和eNOS活性正常化.
- 有益的效果取决于eNOS;AVE9488增强了血管松,减少了超氧化物,并保留了内皮前体细胞.
结论:
- 长期的AVE9488治疗有效地改善了心脏病发作后的LV重塑和收缩功能障碍.
- AVE9488积极调节的分子通路,内皮原生细胞水平和血管运动功能.
- 增强eNOS衍生的NO是一种有前途的治疗策略,用于心脏病发作后心力衰竭.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
01:25Aortic Regurgitation III: Medical Management
598
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
598
01:14Myocarditis III: Medical Management
344
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
344
01:29Heart Failure II: Pathophysiology
2.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
2.1K
01:22Heart Failure VI: Adjunct Therapies
635
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
635
01:29Cardiomyopathy V: Interprofessional Care
761
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
761